INMED PHARMACEUTICALS INC. Payments of Financing Costs
INMED PHARMACEUTICALS INC. (INM) reported Payments of Financing Costs of $1.32 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2023-11-14
- INMED PHARMACEUTICALS INC. payments of financing costs for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- INMED PHARMACEUTICALS INC. payments of financing costs for the quarter ending 2023-03-31 was $63.87K.
- INMED PHARMACEUTICALS INC. payments of financing costs for the quarter ending 2022-12-31 was $684.65K, a 282.23% increase year-over-year.
- INMED PHARMACEUTICALS INC. payments of financing costs for the quarter ending 2022-09-30 was $571.26K, a 48.77% decline year-over-year.
- INMED PHARMACEUTICALS INC. payments of financing costs for fiscal 2023 was $1.32M, a 26.05% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. payments of financing costs for fiscal 2022 was $1.78M, a 10.32% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. payments of financing costs for fiscal 2021 was $1.62M, a 5119.82% increase from fiscal 2020.
- INMED PHARMACEUTICALS INC. payments of financing costs for fiscal 2020 was $30.99K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $63.87K derived: sum of 2 quarters · filed 2023-09-29 | $748.52K derived: sum of 3 quarters · filed 2023-09-29 | $1.32M 10-K · filed 2023-09-29 |
| 2023-03-31 | $63.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $748.52K derived: sum of 2 quarters · filed 2023-05-15 | $1.32M 10-Q · filed 2023-05-15 | $1.81M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $684.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $1.26M 10-Q · filed 2023-02-17 | $1.75M derived: sum of 3 quarters · filed 2023-11-14 | $1.75M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-09-30 | $571.26K 10-Q · filed 2023-11-14 | $1.06M derived: sum of 2 quarters · filed 2023-11-14 | $1.06M derived: sum of 3 quarters · filed 2023-11-14 | $1.24M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $490.54K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $490.54K derived: sum of 2 quarters · filed 2023-09-29 | $669.66K derived: sum of 3 quarters · filed 2023-09-29 | $1.78M 10-K · filed 2023-09-29 |
| 2022-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $179.12K derived: sum of 2 quarters · filed 2023-05-15 | $1.29M 10-Q · filed 2023-05-15 | $1.38M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $179.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $1.29M 10-Q · filed 2023-02-17 | $1.38M derived: sum of 3 quarters · filed 2023-02-17 | $1.80M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-09-30 | $1.12M 10-Q · filed 2022-11-14 | $1.20M derived: sum of 2 quarters · filed 2022-11-14 | $1.62M derived: sum of 3 quarters · filed 2022-11-14 | $2.67M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $83.18K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $500.81K derived: sum of 2 quarters · filed 2022-09-23 | $1.55M derived: sum of 3 quarters · filed 2022-09-23 | $1.62M 10-K · filed 2022-09-23 |
| 2021-03-31 | $417.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $1.47M derived: sum of 2 quarters · filed 2022-05-13 | $1.53M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $1.12M 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $64.65K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $30.99K 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |